## Supplementary Table 1. Quality assessments of the RCTs included in the study by using the Jadad scale

Items	Xie 2013	Notarangelo 2018
Was the study described as randomized?	1	1
Was the method of randomization appropriate?	1	1
Was the study described as blinded?	0	1
Was the method of blinding appropriate?	0	0
Was there a description of withdrawals and	1	1
dropouts?		
Total	3	4

## Supplementary Table 2. Quality assessments of the Non-RCTs included in the study by using Newcastle-Ottawa Scale for cohort studies

Items	Sánchez-Ramos 2016	Shen 2016	Ozawa 2018
Selection			
Representativeness of the exposed cohort	*	*	*
Selection of the non exposed cohor		*	*
Ascertainment of exposure	*	*	*
Demonstration that outcome of interest was not present at start of study	*	*	*
Comparability			
Comparability of cohorts on the basis of the design or analysis	*	*	*
Outcome			
Assessment of outcome	*	*	*
Was follow-up long enough for outcomes to occur	*	*	*
Adequacy of follow up of cohorts	*	*	*
Total	7	8	8

## Supplementary Table 3. The distribution of genotypes in Genotype-guided groups in included studies

Genotype	Xie	Sánchez-Ramos	Notarangelo	Shen	Ozawa	
	2013	2016	2018	2016	2018	
	N=301	N=719	N=888	N=628	N=65	
CYP2C19*2						
*1/*1	47.5%	72.87%	66.5%	43%	26.7%	
*1/*2	37.9%	24.29%	29.2%	39.2%	30.4%	
*2/*2	5.3%	2.84%	4.3%	9.1%	4.3%	
CYP2C19*3			NA			
*1/*1		0				
*1/*3	4.7%	0		5.8%	13.0%	
*3/*3	0.7%	0		0.3%	0%	
*2/*3	4.0%	NA		2.6%	17.4%	
CYP2C19*17	NA	NA		NA	NA	
*1/*1			60.9%			
*1/*17			31.3%			
*17/*17			7.8%			
ABCB1	NA			NA	NA	
CC		29.02%	26.5%			
CT		51.42%	47.1%			
TT		19.56%	26.4%		_	

NA: Not Applicable

## Supplementary Table 4. The occurrences of events for each outcome in included studies

	_	te outcome	Death (G/C)		MI (G/C)		Stroke (G/C)		Vessel revascularization (G/C)		Bleeding events (G/C)	
Xie 2013	8/301	27/299	1/301	9/299	1/301	7/299	1/301	2/299	5/301	9/299	4/301	11/299
Sánchez-Ramos 2016	32/317	59/402	4/317	13/402	27/317	41/402	2/317	8/402	12/317	22/402	13/317	19/402
Notarangelo 2018	71/448	114/440	28/448	34/440	21/448	47/440	5/448	7/440	NA	NA	17/448	26/440
Shen 2016	13/309	30/319	4/309	8/319	5/309	13/319	NA	NA	4/309	9/319	25/309	19/319
Ozawa 2018	1/24	9/41	1/24	5/41	0/24	0/41	0/24	0/41	0/24	3/41	0/24	2/41

G: Genotype-guided group; C: Conventional treatment group; MI: Myocardial Infarction; NA: Not Applicable